There are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes simplex virus type 2. The candidate is currently in phase 1/2 trial ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

GSK is also working with SK Bioscience on a phase 1/2 study for a vaccine based on self-assembling nanoparticle technology developed by the University of Washington, with funding from CEPI and the ...

Symptomatic HSV-2 infection is also associated with an ... and therapeutics that reduce severity and viral load. Another company, GSK, completed a vaccine trial in September 2024, but the vaccine ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...

RSV vaccine Arexvy is likely to have a muted sales ramp in the near term. GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...